Exelixis, Inc.
EXEL

$7.6 B
Marketcap
$26.66
Share price
Country
$0.42
Change (1 day)
$27.83
Year High
$18.64
Year Low
Categories

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

marketcap

Earnings for Exelixis, Inc. (EXEL)

Earnings in 2023 (TTM): $257.52 M

According to Exelixis, Inc.'s latest financial reports the company's current earnings (TTM) are $257.52 M. The earnings displayed on this page is the company's Pretax Income.

Earnings history of Exelixis, Inc.

Annual Earnings

Year Income Before Tax Net Income
2023 $257.52 M $207.77 M
2022 $234.35 M $182.28 M
2021 $294.15 M $231.06 M
2020 $130.84 M $111.78 M
2019 $398.11 M $321.01 M
2018 $452.09 M $690.07 M
2017 $158.58 M $154.23 M
2016 $-70,222,000 $-70,222,000
2015 $-169,682,000 $-169,737,000
2014 $-268,724,000 $-268,542,000
2013 $-244,856,000 $-244,760,000
2012 $-147,538,000 $-147,645,000
2011 $76.99 M $75.7 M
2010 $-92,402,000 $-92,330,000
2009 $-140,843,000 $-135,220,000
2008 $-162,854,000 $-162,854,000
2007 $-86,381,000 $-86,381,000
2006 $-101,492,000 $-101,492,000
2005 $-94,810,000 $-84,404,000
2004 $-137,245,000 $-137,245,000
2003 $-95,119,000 $-94,774,000
2002 $-84,534,000 $-86,130,000
2001 $-84,678,000 $-71,186,000
2000 $-80,958,000 $-75,311,000
1999 $ $-18,700,000
1998 $-15,666,000 $-15,666,000